BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31805655)

  • 1. Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC
    Piyasiridej S; Townamchai N; Udomkarnjananun S; Vadcharavivad S; Pongpirul K; Wattanatorn S; Sirichindakul B; Avihingsanon Y; Tungsanga K; Eiam-Ong S; Praditpornsilpa K
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31805655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
    Kamar N; Marquet P; Gandia P; Muscari F; Lavayssière L; Esposito L; Guitard J; Canivet C; Peron JM; Alric L; Suc B; Saint-Marcoux F; Rostaing L
    Ther Drug Monit; 2009 Aug; 31(4):451-6. PubMed ID: 19531983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients.
    Larpparisuth N; Pinpaiboon S; Ratchawang N; Promraj R; Skulratanasak P; Vongwiwatana A; Premasathian N
    Transplant Proc; 2019 Oct; 51(8):2629-2632. PubMed ID: 31471014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Weber LT; Lamersdorf T; Shipkova M; Niedmann PD; Wiesel M; Zimmerhackl LB; Staskewitz A; Schütz E; Mehls O; Oellerich M; Armstrong VW; Tönshoff B
    Ther Drug Monit; 1999 Oct; 21(5):498-506. PubMed ID: 10519445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients.
    Zhang J; Sun Z; Zhu Z; Yang J; Kang J; Feng G; Zhou L; Zuo L; Luo Y; Zhang X
    Front Pharmacol; 2018; 9():908. PubMed ID: 30150939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients.
    Armstrong VW; Tenderich G; Shipkova M; Parsa A; Koerfer R; Schröder H; Oellerich M
    Ther Drug Monit; 2005 Jun; 27(3):315-21. PubMed ID: 15905802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients.
    Xiang H; Zhou H; Zhang J; Sun Y; Wang Y; Han Y; Cai J
    Front Pharmacol; 2021; 12():652333. PubMed ID: 33912061
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients.
    Cai W; Cai Q; Xiong N; Qin Y; Lai L; Sun X; Hu Y
    Transplant Proc; 2018 Jun; 50(5):1298-1304. PubMed ID: 29735215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
    Cortinovis M; Gotti E; Pradini S; Gaspari F; Perico N
    Transplantation; 2011 Sep; 92(5):550-6. PubMed ID: 21709602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
    Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant.
    Weber LT; Hoecker B; Armstrong VW; Oellerich M; Tönshoff B
    Ther Drug Monit; 2008 Oct; 30(5):570-5. PubMed ID: 18758392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of limited sampling strategy for mycophenolic acid area under the curve considering postoperative days in living-donor renal transplant recipients with concomitant prolonged-release tacrolimus.
    Enokiya T; Nishikawa K; Muraki Y; Iwamoto T; Kanda H; Sugimura Y; Okuda M
    J Pharm Health Care Sci; 2017; 3():17. PubMed ID: 28652924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome.
    Benz MR; Ehren R; Kleinert D; Müller C; Gellermann J; Fehrenbach H; Schmidt H; Weber LT
    Ther Drug Monit; 2019 Dec; 41(6):696-702. PubMed ID: 31425441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.